MetaCap

Alpha Teknova Inc. (TKNO)

NASDAQ: TKNOHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD

7.63-0.18 (-2.30%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TKNO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$479.95M
EPS (TTM)
-$0.30
52-week range
1.91 – 9.48
Day range
7.52 – 7.80
Volume / Avg
254.65K / 437.31K
Beta
—

52-week range

$1.91$9.48

TKNO stock today

Shares of Alpha Teknova (TKNO) finished lower on Nov 20 at $7.63, a drop of 2.30% or $0.18 per share, versus the S&P 500's 3.70% decline. At this level, TKNO sits in the middle of its 52-week range of $1.91 to $9.48: 19.5% below the high, set on Sep 25, 2026 and 299.5% above the low. TKNO is up 100.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 77.4%.

Alpha Teknova has posted a net loss over the last twelve months (EPS of -$0.30), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Alpha Teknova

Company profile

Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company' primary products include pre-poured media plates for cell growth and cloning; liquid microbial culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification.

Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
CEO
Mr. Stephen Gunstream
Headquarters
Hollister, CA
Employees
158
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Alpha Teknova generated $40.5 million in revenue, up 7.4% from fiscal 2024, its 2nd consecutive year of revenue growth. Alpha Teknova reported a net loss of $17.3 million, compared with a loss of $26.7 million a year earlier. Gross margin was 33.2% (up from 19.2%) and operating margin -41.9%.

Alpha Teknova annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$40.52M$37.74M$36.68M$41.42M$36.89M
Growth+7.35%+2.89%-11.43%+12.27%+17.88%
Net income$-17.26M$-26.75M$-36.78M$-47.47M$-9.80M
EPS (diluted)$-0.32$-0.57$-1.16$-1.69$-0.61

Analyst forecast

Forecast

Consensus (8 analysts)

none

Avg. price target

$9.83+28.83%

  • Strong buy 0
  • Buy 7
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $12.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 4, 2026
EPS actual vs est.
$-0.08 vs $-0.06
Surprise
-33.33%

TKNO news

All TKNO news

Alpha Teknova peers

Health Care sector
TKNO peer companies
CompanyPrice% ChgMarket capCompare
MYGNMyriad Genetics Inc.5.46-1.44%$523.74Mvs TKNO
QDELQuidelOrtho Corporation8.32-6.73%$570.86Mvs TKNO
QUITAchieve Life Sciences Inc.5.56-5.28%$573.25Mvs TKNO
NNNNAnbio Biotechnology Class A3.32-9.04%$145.72Mvs TKNO
ICCCImmuCell Corporation10.92-2.41%$99.28Mvs TKNO
IMDXInsight Molecular Diagnostics Inc.1.97+18.67%$80.88Mvs TKNO
VNRXVolitionRX Limited0.1621-1.58%$5.85Mvs TKNO
TRIBTrinity Biotech plc ADR6.24+13.76%$5.07Mvs TKNO

Indexes, lists and sector

Alpha Teknova stock FAQ

What is Alpha Teknova's stock price today?

TKNO last traded at $7.63 as of Nov 20, 4:00 PM EST, down 2.30% on the day. Prices are delayed at least 15 minutes.

Who is Alpha Teknova's CEO?

Mr. Stephen Gunstream is the chief executive officer of Alpha Teknova Inc., which has about 158 employees.

What is the TKNO 52-week high?

The 52-week high for TKNO is $9.48 and the 52-week low is $1.91. The stock is currently 19.5% below its high.

Compare TKNO